Home > Healthcare > Medical Devices > Therapeutic Devices > Xenotransplantation Market

Xenotransplantation Market Trends

Report ID: GMI6136
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Xenotransplantation Market Trends

Advancements in organ preservation technologies, including machine perfusion and cryopreservation methods, enhance the viability and quality of xenogeneic organs.Similarly, advances in genetic engineering techniques, such as CRISPR-Cas9 allows healthcare professionals to modify animal genomes to create genetically engineered pigs or other animals with organs that are more compatible with human recipients. Further, increasing adoption of robotics in minimally invasive surgical techniques will provide potential to improve the precision and safety of xenotransplantation procedures. Robotic-assisted surgery can enhance surgical outcomes and reduce post-operative complications.

Authors: Mariam Faizullabhoy , Pratiksha Kamthe

Frequently Asked Questions (FAQ) :

Global market for xenotransplantation was valued at USD 12.7 billion in 2022 and is estimated to account for USD 29.9 billion by 2032, backed by the ongoing R&D in genetic engineering, immunosuppressive therapies, and organ preservation technologies.

The transplant diagnostics segment garnered over USD 5.4 billion in 2022 owing to the growing chronic diseases burden worldwide that leads to surge in the number of organ failure cases.

U.S. market accounted for USD 7 billion in 2022 and will witness considerable market growth during 2023-2032, attributed to the growing prevalence of chronic diseases such as end-stage renal disease, heart failure, and liver failure in the region.

Novartis AG, Immerge BioTherapeutics, Inc., United Therapeutics Corporation, Infigen, Inc., eGenesis, Inc., NZeno Limited, Preservation Solutions, Inc., Xeno Transplants Corporation, F. Hoffmann-La Roche Ltd. and OrganOX Limited among others.